Skip to main content
SpringerLink
Log in

Einfluß von Pseudomonas-Immunglobulin auf die antibakterielle Aktivität menschlicher Phagozyten

Influence of a Pseudomonas-immunoglobulin on the bactericidal activity of human polymorphonuclear leukocytes

  • Published:
Infection Aims and scope Submit manuscript

Zusammenfassung

Untersucht wurde der Einfluß eines Pseudomonas-Immunglobulins auf dieIn vitro-Bakterizidie, Phagozytose und Abtötung vonPseudomonas aeruginosa durch menschliche polymorphkernige neutrophile Leukozyten in aktivem und inaktivem Serum. In aktivem Serum führte das Immunglobulin zu keiner Bakteriolyse, jedoch wurde die Leukozyten-Bakterizidie verstärkt (p ≤ 0,05); in inaktivem Serum war kein Einfluß meßbar. Die Phagozytose wurde sowohl in aktivem als auch in inaktivem Serum bis zu einer Volumenkonzentration von 10%, entsprechend 5 mg IgG/ml gesteigert, 15% zeigte dagegen eine geringere, der von 5% entsprechende, Wirkung. Somit war das Immunglobulin aufgrund seiner hohen Antikörper-Konzentration in der Lage, auchin vitro die Abtötung vonP. aeruginosa durch menschliche polymorphkernige neutrophile Leukozyten zu verstärken.

Summary

Thein vitro influence of a pseudomonas immunoglobulin in active and inactivated serum on the bactericidal activity and phagocytosis of human polymorphonuclear leukocytes was evaluated againstPseudomonas aeruginosa. No lysis of the bacteria could be found in either serum, however, the bactericidal activity of the leukocytes was significantly enhanced in active serum (p ≤ 0,05), whereas no effect was measurable in inactivated serum. Phagocytosis could be increased in concentrations of 10% immunoglobulin, (equivalent to 5 mg IgG/ml); however, a concentration of 15% showed a lower phagocytosis index which was comparable to that in the 5% preparation. This immunoglobulin proved to be able to support the bacterial phagocytosis and killing ofP. aeruginosa by human polymorphonuclear leukocytesin vitro.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Braveny, I. Pseudomonas aeruginosa. 2. Auflage W. Zuckschwerdt Verlag, München 1986.

    Google Scholar 

  2. Stevens, R. M., Teres, D., Skillmann, J. J., Feingold, D. S. Pneumonia in an intensive care unit. Arch. Intern. Med. 134 (1974) 106.

    Google Scholar 

  3. Bryant, R. E., Hood, C. E., Koenig, M. G. Factors affecting mortality of gram-negative rod bacteremia. Arch. Intern. Med. 127 (1971) 120–128.

    Google Scholar 

  4. Stephan, W., Dichtelmüller, H. Immunglobulin M-Präparat: Herstellung, Eigenschaften und Wirksamkeit. In:Ungeheuer, E., Heinrich, D. (eds.): Bakterien, Endotoxin, Sepsis-Immunglobulin M. Springer Verlag Berlin 1985, pp. 60–66.

    Google Scholar 

  5. Collins, M. S., Roby, R. E. Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens ofPseudomonas aeruginosa. Am. J. Med. 76 (1984) 168–174.

    Google Scholar 

  6. Bassler, M., Just, H.-M., Daschner, F. D. Vergleich der antibakteriellen Aktivität von Azlocillin, Piperacillin, Cefoperazon und Ceftazidim gegenStaphylococcus aureus undPseudomonas aeruginosa in Bouillon, Serum und in Kombination mit polymorphkernigen Leukozyten. In:Knothe, H., Adam, D., Stille, W. (eds).: Ceftazidim. Futuramed-Verlag München 1985, pp. 591–599.

    Google Scholar 

  7. Hässig, A. Intravenous immunoglobulins: Pharmacological aspects and therapeutic use. Vox Sang 51 (1986) 10–17.

    Google Scholar 

  8. Dalhoff, A. Phagozytosebeeinflussung durch Azlocillin, Mezlocillin, auch kombiniert mit Polyglobin. In:Wiedemann, B., Hengstmann, J., Adam., D. (eds.): Securopen® Baypen®. Schattauer Verlag Stuttgart 1984, pp. 41–56.

    Google Scholar 

  9. Alexander, J. W., Stinnett, J. D., Ogle, C. K., Ogle, J. D., Morris, M. J. A comparison of immunologic profiles and their influence on bacteremia in surgical patients with a high risk of infection. Surgery 86 (1979) 94–104.

    Google Scholar 

  10. Ziegler, E. J., McCutchan, J. A., Fierer, J., Glauser, M. P., Sadoff, J. C., Douglas, H., Braude, A. I. Treatment of gram-negative bacteremia and shock with human antiserum to a mutantEscherichia coli. N. Engl. J. Med. 307 (1982) 1225–1230.

    Google Scholar 

  11. Glauser, M. P., Baumgartner, J. D. Septicaemia and shock in gram-negative bacterial infections. In:Morell, A., Nydegger, U. E. (eds.): Clinical use of intravenous immunglobulins. Academic Press, London 1986, pp. 355–361.

    Google Scholar 

  12. Just, H. M., Metzger, M., Vogel, W., Pelka, R. B. Einfluß einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv-Therapie-Station. Ergebnisse einer randomisierten kontrollierten Studie. Klin. Wochenschr. 64 (1986) 245–256.

    Google Scholar 

  13. Duswald, K. H. Zur Pathobiochemie der Leukozyten-Elastase und ausgewählter Plasmaproteine bei Sepsis nach abdominal-chirurgischen Eingriffen. G-I-T-Verlag Ernst Geibeler, Darmstadt 1983.

    Google Scholar 

  14. Neu, J. S., Pelka, R. B. Immunglobuline bei bakteriellen und viralen Infektionen. Fortschr. Med. 100 (1982) 802–809.

    Google Scholar 

  15. Pollack, M. Antibody therapy in gram-negative bacterial disease. In:Morell, A., Nydegger, U. E. (eds.): Clinical use of intravenous immunoglobulins. Academic Press, London 1986, pp. 317–325.

    Google Scholar 

  16. Marget, W., Mar, P. J., Jaspers, L., Possinger, K., Haselberger, H. Preliminary study on administration of high-titer lipid A antibody serum in sepsis and septic shock patients. Infection 13 (1986) 120–124.

    Google Scholar 

  17. Jaspers, L. M., Marget, W., Mar, P. J., Possinger, K., Langecker, P., Hoffmann, K.: High titer anti-lipid A serum in treatment of septic shock. Proceedings IXth International Congress of Infectious and Parasitic Diseases. Munich 1986 vol. 2, pp. 57–58.

  18. Barandun, S., Morell, A., Skvaril, F. Clinical experiences with immunoglobulin for intravenous use. In:Alving, B. M., Finlayson, J. S. (eds.): Immunoglobulins: characteristics and uses of intravenous preparations. US Dept. of Health, and Human Services. Public Health Service Food and Drug Administration, Bethesda 1980, pp. 15–22.

    Google Scholar 

  19. Warren, H. S., Novitsky, T. J., Ketchum, P. A., Roslansky, P. F., Kania, S., Siber, G. R. Neutralization of bacterial lipopolysaccharides by human plasma. J. Clin. Microb. 22 (1985) 590–595.

    Google Scholar 

  20. van Furth, R., Leijh, P. C. J., Klei, F. Correlation between opsonic activity for various microorganisms and composition of gamma-globulin preparations for intravenous use. J. Infect. Dis. 149 (1984) 511–517.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinikhygiene des Universitätsklinikums, Hugstetter Straße 55, D-7800, Freiburg

    H. -M. Just,  M. Termöhlen, M. Pinkawa &  F. D. Daschner

Authors
  1. H. -M. Just
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Termöhlen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Pinkawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. D. Daschner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Just, H.M., Termöhlen, M., Pinkawa, M. et al. Einfluß von Pseudomonas-Immunglobulin auf die antibakterielle Aktivität menschlicher Phagozyten. Infection 15 (Suppl 2), S42–S46 (1987). https://doi.org/10.1007/BF01644191

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01644191

Search

Navigation